[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][vc_single_image image=”11120″ img_size=”200×200″ alignment=”center”][/vc_column_inner][/vc_row_inner][vc_column_text css=”.vc_custom_1609886069314{padding-top: 25px !important;padding-bottom: 25px !important;}”]On Wednesday, November 12, CAC2 had the privilege of hosting Jeffrey Skolnik, MD, US Medical Affairs Leader, Oncology, GlaxoSmithKline and Attending Physician, Children’s Hospital of Philadelphia.
He presented our November All-Member webinar about the industry perspective in pediatric oncology drug development. The views he expresses are his personal observations and not the official position of GSK or any other pharmaceutical company.[/vc_column_text][/vc_column][/vc_row][vc_row css=”.vc_custom_1594763160491{margin-bottom: 100px !important;}”][vc_column][vc_video link=”https://youtu.be/Txrak33zR60″ align=”center”][/vc_column][/vc_row]
